Dr Jeffrey Scott Nine, MD in Tamuning, GU - Pathology

Dr Jeffrey Scott Nine, MD is a Pathology - Forensic Pathology physician based in Tamuning, Guam. Dr Jeffrey Scott Nine is licensed to practice in Guam (license number M-2299) and his current practice location is Guam Office Of The Chief Medical Examiner, 325 Duenas Drive, Tamuning, Guam. He can be reached at his office (for appointments etc.) via phone at (671) 646-9363.

NPI number for Dr Jeffrey Scott Nine is 1285649756 and his current mailing address is Guam Office Of The Chief Medical Examiner, 325 Duenas Drive, Tamuning, Guam. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1285649756.

Contact Information

	Dr Jeffrey Scott Nine, MD
	Guam Office Of The Chief Medical Examiner, 325 Duenas Drive, Tamuning, GU 96913
	(671) 646-9363
	(671) 646-8860

Physician's Profile

Full Name	Dr Jeffrey Scott Nine
Gender	Male
Speciality	Pathology - Forensic Pathology
Location	Guam Office Of The Chief Medical Examiner, Tamuning, Guam
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1285649756
Provider Enumeration Date: 07/30/2006
Last Update Date: 02/01/2023

Medical Identifiers

Medical identifiers for Dr Jeffrey Scott Nine such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1285649756	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207ZF0201X	Pathology - Forensic Pathology	28464 (Arizona)	Secondary
207ZF0201X	Pathology - Forensic Pathology	MD051862L (Pennsylvania)	Secondary
207ZP0102X	Pathology - Anatomic Pathology & Clinical Pathology	28464 (Arizona)	Secondary
207ZP0102X	Pathology - Anatomic Pathology & Clinical Pathology	MD051862L (Pennsylvania)	Secondary
207ZP0102X	Pathology - Anatomic Pathology & Clinical Pathology	M-2299 (Guam)	Secondary
207ZF0201X	Pathology - Forensic Pathology	M-2299 (Guam)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Jeffrey Scott Nine is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Jeffrey Scott Nine, MD Guam Office Of The Chief Medical Examiner, 325 Duenas Drive, Tamuning, GU 96913 Ph: (671) 646-9363	Dr Jeffrey Scott Nine, MD Guam Office Of The Chief Medical Examiner, 325 Duenas Drive, Tamuning, GU 96913 Ph: (671) 646-9363

News Archive

A better understanding of the gut-brain axis may lead to new treatments for neurological disorders

Anyone who has experienced "butterflies in the stomach" before giving a big presentation will be unsurprised to learn there is a physical connection between their gut and their brain.

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its pivotal trial of Captisol-enabled (propylene glycol-free) Melphalan met its primary end points.

Lack or excess of CaM kinase II affects heart muscle cell stiffness

A certain enzyme, the CaM kinase II, keeps the cardiac muscle flexible. By transferring phosphate groups to the giant protein titin, it relaxes the muscle cells. This is reported by researchers led by Prof. Dr. Wolfgang Linke of the Institute of Physiology at the Ruhr Universität in the journal Circulation Research. In failing hearts, which don't pump enough blood around the body, the scientists found an overly active CaM kinase II.

Research reveals increased inflammatory activity in patients with frontotemporal dementia

Recent research from the University of Eastern Finland revealed increased inflammatory activity in a subgroup of patients with frontotemporal dementia. Increased inflammation was associated with parkinsonism symptoms and more rapid disease progression.

pSivida submits MAA for Iluvien to UK MHRA

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) for Iluvien®.

Dr Jeffrey Scott Nine, MD - Pathology in Tamuning, GU